… Friedman reports leadership for Istari Oncology; stock and other ownership interests in Istari
Oncology, Diverse Biotech, and Cancer Expert Now; personal fees from Cancer Expert Now…

… In short, a maladapted personality may actually be the one that is particularly prone to
developing CHD and perhaps other diseases as well (Friedman & Booth-Kewley, in press) In sum, …

… Elimination was equally rapid, with a plasma half-life ranging from 1.6 to 1.8 h and a
whole-body clearance of 12 liters/h. The PK of temozolomide was linear and reproducible,with little …

Background A recent genomewide mutational analysis of glioblastomas (World Health
Organization [WHO] grade IV glioma) revealed somatic mutations of the isocitrate dehydrogenase …

A technique was devised for obtaining rate laws and kinetic parameters which describe the
thermal degradation of plastics from TGA data. The method is based on the inter‐comparison …

Malignant cells, like all actively growing cells, must maintain their telomeres, but genetic
mechanisms responsible for telomere maintenance in tumors have only recently been …

Purpose The prognosis for patients with recurrent glioblastoma multiforme is poor, with a
median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal …

Investigated whether the effectiveness of endorser type is dependent on the type of product
being endorsed. 12 fictitious, black-and-white print advertisements were professionally …

THE clinical manifestations of Fanconi's anemia, an autosomal recessive disorder, include
progressive pancytopenia, a predisposition to neoplasia, and nonhematopoietic …

Purpose We evaluated the efficacy of bevacizumab, alone and in combination with
irinotecan, in patients with recurrent glioblastoma in a phase II, multicenter, open-label …